Market research
ZEAL Zealand Pharma A/S ADR
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 814M
- P/E ratio
- Not available
- Analyst target
- 240.78
- Dividend yield
- 0.0%
- Beta
- 1.34
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 814M
- P/E ratio
- Not available
- Analyst target
- 240.78
- Dividend yield
- 0.0%
- Beta
- 1.34
About
About Zealand Pharma A/S ADR
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Research context
Zealand Pharma A/S ADR appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ZEAL discussion.
5 years, 6 months ago
Zealand Pharma A/S is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.8.
Zealand Pharma A/S's total revenue rose by 451.3% to $63M since the same quarter in the previous year.
Its net income has dropped by 96.5% to $-381M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.9% to $-282M since the same quarter in the previous year.
Based on the above factors, Zealand Pharma A/S gets an overall score of 2/5.